Clinical Trials of the Week: Main Line Health is recruiting patients for six lung cancer clinical studies

By Donna Loyle, communications specialist, LIMR

November is Lung Cancer Awareness Month, which makes this an ideal time to highlight the Main Line Health lung cancer clinical trials that currently are recruiting patients. Trials are available for patients diagnosed with small cell (SCLC) and non-small cell lung cancer (NSCLC).

  • E4512 is testing the oral drug crizotinib in patients with NSCLC and are positive for ALK gene.
  • C30610/RTOG 0538 is a radiotherapy study for patients with SCLC confined to one hemithorax.
  • The Alchemist trial (A151216) seeks to advance genetic research related to NSCLC.
  • A081105 is testing the oral drug erlotinib in patients with NSCLC and are positive for EGFR gene.
  • NRG LU002 is studying chemotherapy with or without radiotherapy in patients with NSCLC.
  • Lung-MAP is a master screening protocol for patients with recurrent NSCLC. If assigned to a sub-study, participants undergo a new, targeted cancer therapy or a combination of standard care.

The principal investigators for these trials are Albert DeNittis, MD, and Paul Gilman, MD. For more, email cancertrials@mlhs.org or visit www.mainlinehealth.org/lungclinicaltrials.

This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *